| pubmed-article:9192752 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0035366 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C1518999 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0229601 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C0231221 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C1332710 | lld:lifeskim |
| pubmed-article:9192752 | lifeskim:mentions | umls-concept:C1160185 | lld:lifeskim |
| pubmed-article:9192752 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:9192752 | pubmed:dateCreated | 1997-7-10 | lld:pubmed |
| pubmed-article:9192752 | pubmed:abstractText | The potential of hematopoietic stem cells (HSCs) from human immunodeficiency virus type-1 (HIV-1)-infected individuals, eg, self-renewal and multilineage differentiative capacity, might be perturbed due to the underlying disease. In this study, we assessed the HSC activity in the CD34+ Thy-1+ cell population of peripheral blood stem cells (PBSCs) of three asymptomatic HIV-1-infected individuals after granulocyte colony-stimulating factor (G-CSF; 10 microg/kg/d) mobilization. On day 4 of G-CSF treatment, 0.8% to 1% of the total blood mononuclear cells were CD34+. Leukapheresis followed by a two-step cell isolation process yielded a CD34+ Thy-1+ cell population of high purity (76% to 92% CD34+ Thy-1+ cells). This cell population showed no evidence of HIV-1-containing cells based on a semiquantitative HIV-1 DNA polymerase chain reaction. Furthermore, the purified cells showed normal hematopoietic potential in in vitro clonogenic assays. Successful gene transfer into committed progenitor cells (colony-forming units-cells) and more primitive stem/progenitor cells (long-term culture colony-forming cells) could be shown after amphotropic retroviral transduction. These data provide evidence that the CD34+ Thy-1+ stem cell compartment can be mobilized and enriched in early stage HIV-1-infected patients. Furthermore, successful transduction of this cell population as a prerequisite for stem cell-based clinical gene therapy protocols was demonstrated. | lld:pubmed |
| pubmed-article:9192752 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9192752 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9192752 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9192752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9192752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9192752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9192752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9192752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9192752 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9192752 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9192752 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:ZaiaJ AJA | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:KaneshimaHH | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:FormanS JSJ | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:SniecinskiII | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:BöhnleinEE | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:JunkerUU | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:MoorJ FJF | lld:pubmed |
| pubmed-article:9192752 | pubmed:author | pubmed-author:KalfoglouC... | lld:pubmed |
| pubmed-article:9192752 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9192752 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9192752 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:9192752 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9192752 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9192752 | pubmed:pagination | 4299-306 | lld:pubmed |
| pubmed-article:9192752 | pubmed:dateRevised | 2006-4-21 | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:meshHeading | pubmed-meshheading:9192752-... | lld:pubmed |
| pubmed-article:9192752 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9192752 | pubmed:articleTitle | Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor. | lld:pubmed |
| pubmed-article:9192752 | pubmed:affiliation | Progenesys Program, Systemix Inc, Palo Alto, CA 94304, USA. | lld:pubmed |
| pubmed-article:9192752 | pubmed:publicationType | Journal Article | lld:pubmed |
